Related Experiment Video

Updated: Jul 9, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Pllans-II: Unveiling the Action Mechanism of a Promising Chemotherapeutic Agent Targeting Cervical Cancer Cell

Alejandro Montoya-Gómez1, Fiorella Tonello2, Barbara Spolaore3

  • 1Grupo de Nutrición, Facultad de Salud, Universidad del Valle, Cali 760043, Colombia.

Cells
|December 9, 2023
PubMed

Insights

Snake venom phospholipase A2 (Pllans-II) shows potential as a cervical cancer treatment. It selectively targets cancer cells by disrupting their adhesion, offering a promising alternative with fewer side effects.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Cervical cancer chemotherapy often causes severe side effects, impacting patient quality of life.
  • There is a critical need for novel antitumor agents derived from natural sources with improved safety profiles.
  • Previous studies identified Pllans-II, a phospholipase A2 from snake venom, as selectively cytotoxic to cervical cancer cell lines.

Purpose of the Study:

  • To investigate the mechanism of action of Pllans-II in HeLa cervical cancer cells.
  • To evaluate the potential of Pllans-II as a prototype for a new cervical cancer chemotherapeutic drug.

Main Methods:

  • Cell-based assays were used to assess the cytotoxic effects of Pllans-II on HeLa cells.
  • Analysis of cytoplasmic membrane integrity and mitochondrial membrane potential was performed.
  • Investigated the role of Pllans-II in blocking cell adhesion and disrupting integrin-fibronectin interactions.

Main Results:

  • Pllans-II induced cytotoxicity in HeLa cells without compromising cytoplasmic or mitochondrial membrane integrity.
  • Cell death was linked to the inhibition of α5β1 integrin and fibronectin interactions.
  • Pllans-II significantly reduced cancer cell adhesion, proliferation, and survival pathways.

Conclusions:

  • Pllans-II exhibits selective cytotoxic effects on cervical cancer cells through a novel mechanism involving adhesion disruption.
  • Pllans-II represents a promising lead compound for the development of targeted cervical cancer therapies with potentially reduced side effects.
Keywords:
antitumor potentialbioprospectingmembrane receptor targetphospholipase A2snake venomtranscriptomic analysis

More Related Videos

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

959
Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

18.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
167